OnCo
peoplePerson

Tae-You Kim

A GI oncologist and genomics researcher who leads precision oncology and colorectal cancer trials at Seoul National University.

Tae-You Kim's group studies the genomic and epigenetic landscape of colorectal and gastric cancer and runs biomarker-driven trials, contributing to the Korean precision oncology programme and to global colorectal studies.

Role
Professor of Internal Medicine; gastrointestinal oncology and cancer genomics
Specialisms
Colorectal cancerGastric cancerCancer genomicsPrecision oncology

Key papers

1top
rctNew England Journal of Medicine 2020changed practice
IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer

Patients with advanced liver cancer and good liver function should be offered atezolizumab plus bevacizumab (or durvalumab plus tremelimumab) rather than sorafenib as first treatment; median survival is now around 19 months and about a quarter of patients respond. Endoscopy to treat varices before starting bevacizumab is essential because of bleeding risk. Patients with poorer liver function (Child-Pugh B) or autoimmune disease or transplants were not studied.

Connected

5top

Pages like this

not linked directly; found by shared links

cancers

2
Colorectal cancerGastric & gastro-oesophageal junction cancer

technologies

1
Comprehensive genomic profiling

institutions

1
Seoul National University Hospital

key papers

1
IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer